Ceftazidime was used as the only intravenous agent for treating lower respiratory tract infections in patients with cystic fibrosis. The risks of inducing ft lactamases and conferring antibiotic resistance are high when monotherapy is used; so the emergence of resistant bacteria was studied prospectively in the sputum of 120 patients. The mean age of patients was 9-0 (range 0 3-25) years and there were equal numbers of male and female patients. Pseudomonas aeruginosa was the only ceftazidime resistant bacterium to be isolated from the respiratory tract, and was identified only in chronically colonised patients. Ceftazidime resistance occurred in 103 (14%) of 750 P aeruginosa isolates, and in 16 of 36 chronically colonised patients. Ceftazidime resistant organisms were isolated from the faeces of 17 of 64 patients investigated. Eighty two per cent of the resistant faecal organisms were single isolates: the same resistant organism in faeces was isolated from successive samples in only two patients. In no case was the ceftazidime resistant enteric isolate the same as that from sputum. Patients chronically colonised by P aeruginosa did not harbour ceftazidime resistant enteric organisms any more than non-colonised patients. The use of ceftazidime as a single intravenous agent in treating chest exacerbations in cystic fibrosis does not induce a reservoir of ceftazidime resistant bacteria.
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Results
Oropharyngeal and lower airway bacterial flora were determined in 120 patients for the presence of ceftazidime resistant bacteria, and faecal flora in 64. Sixty five patients (54% of the clinic population) received 185 courses of ceftazidime during the study. One hundred and thirty three courses (72%) were given to patients with chronic colonisation by P aeruginosa (more than six months).
RESPIRATORY FLORA Throat and cough swabs and sputum samples were cultured on 2480 occasions. The most frequent isolates were P aeruginosa (750; 30%), Haemophilus influenzae (370; 15%), Staphylococcus aureus (298; 12%), H influenzae plus S aureus (180; 7 5%), others (228; 9 5%). No potentially pathogenic isolate was obtained in 654 (26%) samples taken.
P aeruginosa was isolated from the respiratory tract in 66 patients (55%), of whom 36 (30%) were chronically colonised (for more than six months). The mean age at which chronic P aeruginosa colonisation was recognised was 10 (range 1-23) years.
The figure shows the results of 713 sputum samples (mean 20 per patient) cultured from the 36 patients with chronic P aeruginosa colonisation. Each isolate was categorised as being resistant to aminoglycosides, carboxy and ureido penicillins, ciprofloxacin, or ceftazidime.
One hundred and three P aeruginosa isolates (14%) were resistant to ceftazidime. They were isolated from the sputum of 16 chronically colonised patients, with a frequency of isolation of less than one in three samples collected. Forty five isolates were sensitive to all antibiotics but ceftazidime. All 58 multiresistant isolates (6-3%) This study does not address the question of the temporal relation between the occurrence of resistant isolates and treatment with ceftazidime. Schryvers et all' reported # lactamase production by P aeruginosa in one patient with cystic fibrosis treated with ceftazidime, and noted that resistant strains of P aeruginosa were isolated mainly during treatment. They suggested that bacteria susceptible to ceftazidime flourish before and after the treatment period and have a selective growth advantage. It is not surprising, therefore, that greater numbers of ceftazidime resistant isolates from sputum occurred in the chronically colonised patients who received the greatest number of ceftazidime courses during the study period.
The unique relation between P aeruginosa and patients with cystic fibrosis makes interpretation of in vitro sensitivity studies particularly difficult and, although we have not presented data to show the clinical improvement with intravenous antibiotic use, we have found that a good clinical response is common even when ceftazidime resistant P aeruginosa is isolated from sputum during treatment with ceftazidime. We change antibiotics only in the face of multiply resistant organisms and an absence of clinical improvement.
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